Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is one of the...

• Forbes Global 2000 (#432);
• Fortune 500 (#339);
• Nasdaq 100;
• Russell 3000;
• S&P 500.

Regeneron Pharmaceuticals is a company listed under the stock ticker REGN (US).

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving Regeneron Pharmaceuticals.

• Regeneron Pharmaceuticals has acquired Checkmate Pharmaceuticals (posted on November 29 2022).
• Regeneron Pharmaceuticals has announced the acquisition of Checkmate Pharmaceuticals  (posted on May 31 2022).

View the org chart displaying its 88 main executives

Most searched biographies at Regeneron Pharmaceuticals

• Leonard Schleifer, President, Chief Executive Officer, Director
• Huda Zoghbi, Director
• Marc Tessier-Lavigne, Director

Popular executive movements at Regeneron Pharmaceuticals

• Robert Landry, Executive Vice President, Finance and Chief Financial Officer, will retire in Feb. 2024  (posted on September 11 2023).
• Chris Fenimore who is Senior Vice President and Controller, will be promoted to Chief Financial Officer in Feb. 2024  (posted on September 11 2023).

Create your alert
to follow the executive moves at Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• MedMen has filed for bankruptcy protection  (posted on April 28 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma
• Emma Walmsley - Chief Executive Officer and Director at GSK

Learn more about the Pharmaceuticals industry >

Press releases by Regeneron Pharmaceuticals

• CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis | Regeneron Pharmaceuticals Inc.
• https://newsroom.regeneron.com/node/24391/pdf
• https://newsroom.regeneron.com/node/24386/pdf
• Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) | Regeneron Pharmaceuticals Inc.
• Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial | Regeneron Pharmaceuticals Inc.
• Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020 | Regeneron Pharmaceuticals Inc.
• Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients | Regeneron Pharmaceuticals Inc.
• Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% | Regeneron Pharmaceuticals Inc.
• Press Releases | Regeneron Pharmaceuticals Inc.
• Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO | Regeneron Pharmaceuticals Inc.
• View more press releases Close

Social media about Regeneron Pharmaceuticals

• Regeneron Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Regeneron Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Leonard Schleifer

Call Regeneron Pharmaceuticals at +1 914...

View the org chart

Register to receive your alert

Report an error